Results 211 to 220 of about 35,241 (222)
Some of the next articles are maybe not open access.
FGFR2 inhibition could suppress spermatogenesis.
Journal of Clinical Oncology, 2020e15659 Background: The incidence of cancer among the people of reproductive age is constantly increasing. Although FGF2/FGFR2 expression in the male reproductive tract has been reported, there is no evidence of the impact of FGFRs inhibitors on sperm function.
Ilya Tsimafeyeu +11 more
openaire +1 more source
Cytogenetic and Genome Research, 2000
A cohort of 36 unrelated German patients with craniosynostosis syndromes of the Crouzon and Pfeiffer type were analyzed for FGFR mutations. Mutations in FGFR2 were identified in 25 Crouzon and 5 Pfeiffer syndrome patients, whereas no sequence alterations were found in the remaining patients, even after screening of the relevant parts of FGFR1, FGFR3 ...
W, Kress +4 more
openaire +2 more sources
A cohort of 36 unrelated German patients with craniosynostosis syndromes of the Crouzon and Pfeiffer type were analyzed for FGFR mutations. Mutations in FGFR2 were identified in 25 Crouzon and 5 Pfeiffer syndrome patients, whereas no sequence alterations were found in the remaining patients, even after screening of the relevant parts of FGFR1, FGFR3 ...
W, Kress +4 more
openaire +2 more sources
Modulation of the expression of the FGFR2-IIIb and FGFR2-IIIc molecules in dermatofibroma
Journal of Dermatological Science, 2008[No abstract available]
SKROZA, Nevena +7 more
openaire +3 more sources
Mutation detection in FGFR2 craniosynostosis syndromes
Human Genetics, 1997Five autosomal dominant craniosynostosis syndromes (Apert, Crouzon, Pfeiffer, Jackson-Weiss and Crouzon syndrome with acanthosis nigricans) result from mutations in FGFR genes. Fourteen unrelated patients with FGFR2-related craniosynostosis syndromes were screened for mutations in exons IIIa and IIIc of FGFR2.
Hollway, G. +6 more
openaire +3 more sources
Journal of Clinical Oncology, 2019
3099 Background: FGFR2 genomic alterations (GA) have been described in a variety of solid tumors and emerged as biomarkers for investigational agents undergoing clinical trials. Methods: 201,766 primarily relapsed/refractory malignancies were evaluated with a hybrid-capture based sequencing assay Tumor mutational burden (TMB) was determined on 0.8-1 ...
Russell Madison +19 more
openaire +1 more source
3099 Background: FGFR2 genomic alterations (GA) have been described in a variety of solid tumors and emerged as biomarkers for investigational agents undergoing clinical trials. Methods: 201,766 primarily relapsed/refractory malignancies were evaluated with a hybrid-capture based sequencing assay Tumor mutational burden (TMB) was determined on 0.8-1 ...
Russell Madison +19 more
openaire +1 more source

